Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Further Herceptin information received by PTAC


Media Release

Further Herceptin information received by PTAC

PHARMAC’s clinical advisory committee PTAC today considered further information on the use of Herceptin for early breast cancer.

PTAC, the Pharmacology and Therapeutics Advisory Committee, is a committee of independent doctors with expertise in critical appraisal of trial data, whose role is to provide clinical advice to PHARMAC on pharmaceuticals being considered for subsidy.

PHARMAC’s deputy medical director Dr Dilky Rasiah says the information that has been presented to the regular quarterly meeting of PTAC today, adds to the evidence that has already been reviewed by PTAC at its February and May 2006 meetings.

The new information includes preliminary release of the 23-month follow-up of the one-year treatment arm from the large HERA trial, as well as some further data supplied by pharmaceutical company Roche, which markets Herceptin.

In July PHARMAC and DHBs announced that funding had not been recommended for Herceptin, but that PHARMAC is committed to actively reviewing new evidence that becomes available, says Dr Rasiah.

ENDS

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.